Mercury Laboratories (BOM:538964) Debt-to-Equity : N/A (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Mercury Laboratories Debt-to-Equity?

Mercury Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Mercury Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Mercury Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0.0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mercury Laboratories's Debt-to-Equity or its related term are showing as below:

BOM:538964' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.25 Max: 0.38
Current: 0.09

During the past 11 years, the highest Debt-to-Equity Ratio of Mercury Laboratories was 0.38. The lowest was 0.09. And the median was 0.25.

BOM:538964's Debt-to-Equity is ranked better than
73.11% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs BOM:538964: 0.09

Mercury Laboratories Debt-to-Equity Historical Data

The historical data trend for Mercury Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Laboratories Debt-to-Equity Chart

Mercury Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.23

0.19

0.15

0.13

0.11

Mercury Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.11	N/A	0.09	N/A

Competitive Comparison of Mercury Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mercury Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mercury Laboratories's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Mercury Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mercury Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.367	+	29.17)	/	508.385
	=	0.11

Mercury Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Mercury Laboratories (BOM:538964) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mercury Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mercury Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mercury Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Laboratories Ltd (BOM:538964) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Gorwa Road, 2/13-14, Gorwa Industrial estate, P.B. No. 3001, Vadodara, GJ, IND, 390016

Website

https://www.mercurylabs.com

Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and internationally, of which key revenue is derived from sales made in India.

Mercury Laboratories Headlines

No Headlines